Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5169599 A
Publication typeGrant
Application numberUS 07/576,359
Publication dateDec 8, 1992
Filing dateAug 30, 1990
Priority dateAug 30, 1990
Fee statusLapsed
Also published asWO1992004631A1
Publication number07576359, 576359, US 5169599 A, US 5169599A, US-A-5169599, US5169599 A, US5169599A
InventorsJose P. Joseph, Kiminori Itoh
Original AssigneeTeknekron Sensor Development Corporation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method and apparatus for optically detecting presence of immunological components
US 5169599 A
Abstract
An optical immunosensing device for detecting the presence of an analyte in a liquid sample is fabricated by coating iron phosphate onto a silicon substrate and then etching the iron phosphate layer to obtain steps of varying thickness. Then, a first mip, capable of immunological reaction with the analyte, is immobilized on the iron phosphate steps. In the preferred embodiment, the first mip is chemically bound to the iron phosphate step surface. The presence of the analyte in the liquid sample is detected by visually observing color changes in the steps after contact of the detection zone with the liquid sample. A change in step color is related to increased thickness which can only result from the binding of the analyte to the first mip immobilized on the iron phosphate step. Aluminum phosphate can also be added to the iron phosphate.
Images(1)
Previous page
Next page
Claims(11)
We claim:
1. An apparatus for visually detecting the presence of an analyte which is a member of an immunological pair (mip) in a liquid sample which comprises:
a) a silicon substrate;
b) an iron phosphate layer, coated onto said silicon substrate and etched to form discrete steps of varying iron phosphate thickness; and,
c) a first mip immobilized upon the surface of said iron phosphate steps to form a detection zone
whereby the presence of the analyte which is a second mip in the liquid sample is detected by wetting the detection zone with the liquid sample, and observing any color change in the detection zone resulting from the increased thickness of the iron phosphate steps caused by the binding of the second mip to the first mip immobilized upon the iron phosphate steps in the detection zone.
2. The apparatus of claim 1 wherein said iron phosphate layer further comprises aluminum phosphate.
3. The apparatus of claim 1 wherein an undercoating adhesion layer is provided between the silicon substrate and the iron phosphate layer.
4. The apparatus of claim 1 wherein said first mip is immobilized upon the iron phosphate layer via chemical bonds.
5. An apparatus for visually detecting the presence of an analyte which is a member of an immunological pair (mip) in a liquid sample which comprises:
a substrate having at least one flat surface for receiving a stepped layer;
the stepped layer, coated onto said substrate with at least one step with flat surfaces parallel to the substrate flat surface wherein the reflectivity at a substrate-stepped layer interface is substantially the same as the reflectivity at the interface between the stepped layer and air; and,
a detection zone in which a first mip is immobilized upon step surfaces of the stepped layer, the index of refraction of said immobilized first mip being substantially similar to the index of refraction of said stepped layer,
whereby the presence of the analyte which is a second mip in the liquid sample is detected by wetting the detection zone with the liquid sample, and observing any color change in the detection zone resulting from an increased thickness of the at least one step caused by binding of the second mip to the first mip immobilized upon the at least one step.
6. The apparatus of claim 5 wherein said substrate is silicon.
7. The apparatus of claim 5 wherein said stepped layer comprises iron phosphate.
8. The apparatus of claim 5 wherein said stepped layer comprises a mixture of iron phosphate and aluminum phosphate.
9. The apparatus of claim 5 wherein said at least one step with flat surface is obtained by controlled coating of the stepped layer material onto the substrate.
10. The apparatus of claim 5 wherein said at least one step with flat surface is obtained by etching the stepped layer material at precise conditions.
11. The apparatus of claim 5 wherein said first mip is immobilized in the detection zone via chemical bonds.
Description
TECHNICAL FIELD

This invention relates generally to the optical detection of the presence of antibodies and antigens in liquid samples, and more particularly, to the use of a visible color change brought about by increasing thickness of layers coated upon a substrate as an indication of the presence of the target analyte.

BACKGROUND OF THE INVENTION

The rapid and accurate detection of extremely low concentrations of antigens and antibodies in liquid samples has been recognized as a valuable tool in the diagnosis and treatment of disease and in substance detection for safety, law enforcement, therapy and environmental applications. The development of recombinant DNA and hybridoma techniques has vastly increased the number of antibodies, antigens and haptens which can be detected by immunologically specific reactions and has improved the sensitivity of these detection methods. Previous investigators have worked with competitive assays which utilize radiation (RIA) and fluorescence to qualitatively and quantitatively signal the presence of the analyte (i.e., the substance to be detected). These techniques require expensive reagents and elaborate instrument schemes to detect and measure a signal related to the presence and amount of the target analyte.

The monoclonal antibody sandwich assay technique has also evolved as a quick and accurate method to detect immunological analytes. In the widely used ELISA, an enzyme (rather than radioactive or fluorescent) tagged component has been used to form a tagged antibody sandwich, which upon addition to the enzyme substrate generates a visually detectable calorimetric signal. One drawback of the ELISA technique is that a relatively expensive reagent (enzyme-tagged immunological component) must be used to complete the sandwich.

One analyte detection technique which does not require tagged molecules in order to generate a measurable signal related to the presence and amount of analyte present involves the use of an ellipsometer to detect changes in refractive properties on a flat reflecting surface. These surface refractive property changes occur when a liquid phase antibody/antigen binds to a solid phase antigen/antibody preadsorbed on the flat reflecting surface. The drawback of this technique, (Rothen, A., Helv. Chim. Acta, 33 834 (1950)), is that the ellipsometer is a complex and expensive instrument, making the use of this technique costly.

BioStar (Colorado) has recently developed an "interference slide" technology for detecting immunological analytes in liquid samples. This technique utilizes visual properties of interference, and anti-reflective coatings, to create altered light responses for thickness changes indicative of the target analyte.

The present invention provides an optical immunosensor which is more sensitive than the BioStar device, and which can be used to measure the amount of analyte present in a liquid sample qualitatively, semi-quantitatively, or quantitatively.

It is therefore one object of the present invention to provide films and substrates which are selected to yield distinctly different colors under assay conditions.

It is another object of the present invention to provide an optical immunosensor device fabrication method which is easy and inexpensive.

It is a further object of this invention to provide an optical immunosensor device which can be used to make qualitative, semi-quantitative and quantitative determinations of the analyte present, based upon the color changes resulting from thickness changes and upon comparisons of these colors to known standards.

These and further objects of the present invention will become apparent to the ordinary artisan by reference to the following specifications and drawings.

SUMMARY OF THE INVENTION

According to a preferred embodiment of the present invention, an optical immunosensing device comprises a silicon substrate onto which has been coated a layer of iron phosphate, and optionally aluminum phosphate, silicon dioxide or mixtures thereof. The metal-containing layer is then carefully etched with an etching acid such as phosphoric acid to obtain a plurality of steps, or regions of varying metal-containing layer coating thickness. One member of an immunological pair (mip) is then immobilized upon the metal-containing layer step surfaces, either directly or through the use of reagents which functionalize the surface to permit covalent binding of the proteins to the solid surface. In the preferred embodiment, chemical binding techniques are used to immobilize the first mip to the metal-containing layer surface. The presence of an analyte which is a second mip in a liquid sample is detected by wetting the metal-containing layer steps upon which the first mip is immobilized with the liquid sample. Any second mip/analyte present in the liquid sample is captured by the first mip immobilized upon the metal-containing layer steps. This immunological binding followed by an aminosilane which can be attached to Si-OH and the proteins to the amino group of the silane between first and second mips results in an increase in the metal-containing layer step thickness which is visually manifested by a change in the observed color of that step from a perspective directly above the metal-containing layer step. Semi-quantitative and quantitative analysis of the amount of analyte present in the liquid sample is made possible by comparison of step colors on the unknown device with step colors on a standard device calibrated for known concentrations.

The optical immunosensing device can be fabricated by spin-coating iron phosphate (and optionally, aluminum phosphate, silicon dioxide, or mixtures thereof) in solution onto the surface of a silicon wafer. Then, phosphoric acid is applied to the metal-containing layer for various exposure times to etch a series of metal-containing layer steps of varying thickness. The first mip is then immobilized on the surface of the metal-containing layer steps, either by chemical (covalent) or physical means (adsorption), chemical techniques being preferred.

Optimum sensitivity and performance of the optical immunosensing device is obtained when the reflectivity at the interface between the metal coating and silicon wafer substrate is matched with the reflectivity of the metal-containing layer at the metal-air interface. Further enhancement is possible if the index of refraction of the metal-containing layer steps is matched closely to the index of refraction of the first bound mip.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a plan view of the layers of the optical immunosensing device of the present invention.

FIG. 2 is a plan view during fabrication of the optical immunosensing device, after an iron phosphate layer is deposited upon the silicon substrate, but prior to any etching with phosphoric acid.

FIG. 3 is a plan view during fabrication of the optical immunosensing device, showing the steps of varying thickness etched into an iron phosphate layer with phosphoric acid.

FIG. 4 is a top plan view of the colors visible on various iron phosphate steps, before and after exposure to a liquid sample containing the target analyte.

DETAILED DESCRIPTION OF THE INVENTION

Before describing the optical immunosensing device itself, it is first necessary to define the components of the immunological systems in which the device can be used. While the terms antigen and antibody are commonly used in the scientific literature, it is necessary for present purposes tobecome more accurate and to account for systems in which haptens are subject to immunological binding and detection. It is considered to be within the scope of this invention that if the target analyte of the immunosensing device is an antibody, the immobilized capture phase will actually be an antibody to an antibody. The various types of immunologicalsystems in which the present invention can be used are described in rigorous detail below.

Here, we adopt a series of definitions for purposes of describing the invention accurately with a view towards the various and diverse systems in which it can be used as an immunoassay.

Analyte is used throughout this specification to refer to the compound or composition to be detected and measured, which is a mip and may be a ligand, which is mono- or polyepitopic, that is, having one or plurality of determinant sites, haptenic and antigenic; a single compound or plurality of compounds which share at least one common epitopic or determinant site; or a receptor.

Member of an immunological pair (mip) is used to acknowledge the complimentarity of antigens-antibodies, haptens-antibodies, even antibodies-antibodies. An immunological pair consists of two different molecules wherein one of the molecules has an area on its surface or in a cavity which specifically binds to a particular spatial and polar organization of the other molecule in the pair. The members of the immunological pair are referred to as ligand and receptor (anti-ligand). The term "member" of the immunological pair refers to one "member" of thisbinding pair.

Ligand--any organic compound for which a receptor exists or can be prepared.

Receptor (antiligand)--any macromolecular compound or composition capable of recognizing (having an enhanced binding affinity to) a particular spatial or determinant site. Illustrative receptors include naturally occurring receptors, e.g., thyroxine binding globulin, antibodies, enzymes, Fab fragments, lectins, and the like. The term antibody is employed in this case as illustrative of and to more generally denote receptor.

Antireceptor--in some situations, a receptor can serve a dual function of binding to a ligand and serving as a ligand to a receptor (antireceptor), such that the ligand and the antireceptor, which cannot bind directly to each other, are joined by the receptor to provide for an immunological linkage. Antireceptors may frequently be antibodies, protein A, rheumatoidfactor, Clq. or the like.

The detection zone is used to refer to the metal-containing layer or iron phosphate steps of the optical immunosensing device upon which a first mipis immobilized and which will be used to detect the presence (and amount) of analyte present in a liquid sample. The detection zone may consist of asingle step, and may also be a plurality of steps. The first mip may be chemically bound to the stepped layer surface, or it may be physically adsorbed.

Wetting is intended to cover at least two methods of applying the liquid sample containing the analyte to the detection zone, i.e., the area in which the first mip has been immobilized on the surface of the step: (1) the liquid sample may be applied to the detection zone dropwise, or continuously, through a dropper pipette, or closed container surrounding the detection zone or (2) the entire immunosensing device itself, or just the detection zone alone, may be immersed in the liquid sample to wet the detection zone.

Liquid sample is defined broadly to refer to physiological fluids such as urine, blood--whole serum or plasma, cerebral spinal fluid, ocular lens liquid and saliva; solutions made from swabbing surfaces or to a solution of such bodily fluids and swabs, or to a solution of a solid protein dissolved in a liquid. The essential characteristic of the liquid sample is that the liquid sample must be able to contain the analyte in solution and to wet the detection zone. Otherwise, there can be no immunological binding between mips.

There is a functional aspect of the immunological system which must be accounted for in the design of the optical immunosensing device: there must be a reasonable immunological binding affinity between the selected mips, i.e., the target analyte and the solid-immobilized capture phase. The immunological reaction kinetics must be carefully studied to ensure that the immunological binding between the mips will take place in a reasonable short period of time, that the immunological bond that is formed is sufficiently strong to withstand the flushing action of excess liquid and that the bond is of sufficient duration in time to enable visual observations of the result. While the definition of the exact parameters for each of these kinetic considerations is outside the scope of the present invention, the ordinary artisan will be able to select mipswhich can optimize the instant invention without undue experimentation.

The concentration of the analyte which may be assayed with the optical immunosensing device will generally vary from about 10-4 to 10-15, more usually from about 10-6 to 10-13 M. Considerations such as whether the assay is qualitative, semi-quantitativeor quantitative and the particular detection technique will normally determine the sensitivity of the device.

The fundamental components of the device 2 are shown in FIG. 1. Onto the smooth surface of a substrate 4, a transparent thin film 6 is deposited. This film 6 is etched to obtain first step 8, second step 10 and third step 12. Then, mip is immobilized upon step surfaces 8, 10 and 12 either by chemical bonds or by physical means, to obtain first mip on first step 14, first mip on second step 16 and first mip on third step 18.

The selection of the substrate 4 is dependent upon the intensity of the light reflected at the interface between the substrate 4 and the film 6, and upon the intensity of the light reflected at the film 6--air interface. Reflectivity at a particular interface is large when the differences in indices of refraction (n) of the two materials forming the interface are large. Thus, nsub >>nfilm >>nair is desired. Since nfilm is always much larger than nair, this condition is easily satisfied. nsub >>nfilm can be satisfied by the use of metallic substrates (e.g. ncr =3.0), but if the substrate is too shiny, the light reflected at the film-substrate interface becomes more intense than the light reflected at the film-air interface, thus obscuringthe signal, i.e., interference color change. This makes silicon and titanium desirable substrate materials. On the other end of the spectrum, substrate materials with low indices of refraction provide a weak reflection of light at the substrate-film interface. This also leads to a weak signal. For example, glass shows weak interference colors when it is coated with dielectrics. In particular, a glass plate shows practically nointerference colors when it is coated with SiO2 because glass has nsub =1.51 which is very close to that of SiO2 (nsub =1.47).

Physical coating techniques and chemical coating techniques can be used to apply a transparent thin film 6 to the substrate 4. Vacuum deposition may be used. Spin-coating is very simple and effective if it can be used with the desired film material. For example, TiO2, SiO2 and FePO4 can be spin-coated from appropriate solutions even though the mechanisms of film-forming are different. TiO2 and SiO2, and mixtures thereof, are formed by a sol-gel process, whereas FePO4 is not. One chemical method which can be used to apply the film is dip-coating. TiO2, SiO2 and their mixtures, are materials which are suitable for this method. FePO4 however, cannot be applied via dip-coating because the film lifted out of solution is attacked by the solvent vaporized and condensed on the film.

Steps in the thin film 6 can be made either during the coating process, or after the film has been coated on the substrate. The procedure selected isa function of the film material and how this material has been coated on the substrate. Since TiO2 -SiO2 mixtures can be applied to the substrate via the dip-coating method, steps can be made during the dip-coating process. Many materials, which can be applied via vacuum deposition, can be formed into steps during the deposition procedure by moving an appropriate shutter stepwise.

In one of the preferred embodiments using iron phosphate, step-formation takes place after the entire film 6 has been deposited on the silicon wafer substrate 4. This is most easily explained with reference to FIGS. 2and 3. After the iron phosphate layer has been applied to the silicon wafersubstrate 4, the iron phosphate film 6 is then etched with phosphoric acid in order to obtain first step 8, second step 10 and third step 12. The steps 8, 10 and 12 are carefully formed by using a mask which exposes the desired surface area to the etching acid, while shielding all other surfaces. The depth of the etch is controlled by the amount of time the phosphoric acid is permitted to act upon the iron phosphate surface. Any number of steps can be formed in this way. The most significant limitationon the size and number of steps is that one visually observes the result ofthe assay from a perspective directly above the step surfaces.

After the steps have been formed in the iron phosphate layer 6, mip is immobilized upon the step surfaces to obtain first mip on first step 14, first mip on second step 16 and first mip on third step 18, as shown in FIGS. 1 and 4. The protein can be immobilized by chemical (covalent) binding, or by physical methods such as adsorption. We have found chemicalbinding to be substantially more suited to the desired immobilization. In either case, the protein must be immobilized on the iron phosphate step surface so that it will not be released into the liquid sample when the detection zone is wetted with the liquid sample.

Before antibody can be immobilized on the surface of the thin film by chemical means, the appropriate functional groups need to be present on the surface of the film. Untreated iron phosphate film does not have the necessary surface functional groups. Thus, in our preferred embodiment, the surface of the iron phosphate film is treated with TiO2 or SiO2 to obtain hydroxyl groups on the surface of the iron phosphate film. Then, we use a cross-linking agent, amino silane, and a bifunctionalagent like glutaraldehyde to immobilize the antibody on the surface of the film. The antibody should be dissolved in a buffer solution to prevent theprotein from denaturing. This and similar techniques are well known in the literature. See, e.g., Weetal, Immobilized Enzymes, Antigens, Antibodies and Peptides, Published by Marcel Dekker, Inc., N.Y., N.Y., 1975.

Other protein immobilization techniques (both physical and chemical) are considered to be within the scope of this invention. When these other techniques are used, two important considerations are the stability of theprotein immobilization to the film surface so that quantitative results maybe obtained when the detection zone is wetted with the liquid sample; and, the geometric configuration of the immobilized protein to insure that the epitopic sites relevant to the immunoassay are actually exposed to the target analyte present in the liquid sample. Some of these immobilization techniques involve the covalent coupling of proteins to the thin film layer. See Weetal, Immobilized Enzymes, Antigens, Antibodies and Peptides,Published by Marcel Dekker, Inc., N.Y., N.Y. (1975), the relevant portions of which are incorporated by reference. Other immobilization methods involve physical processes such as adsorption.

We now turn to a description of the fabrication of the presently preferred embodiment. In summary, there are seven process steps. In the first step, we obtain a clean silicon wafer, or other suitable substrate. Second, we apply an undercoating adhesion layer if it is necessary. Then, iron phosphate is coated onto the substrate in a single layer, which is followed by etching to obtain iron phosphate steps of varying thickness. In the fifth step, a top oxide layer of either TiO2 or SiO2 is provided to give surface hydroxyl groups capable of participating in the mip-immobilization reaction. This top oxide layer surface is then treated with a chemical cross-linking agent, if necessary. In the final step, antibody or protein is applied to the top oxide layer to obtain the immunoreactive surface required for sensing, i.e. immobilized first mip.

When a silicon wafer is used, its surface is normally clean enough so that no further surface cleaning is required prior to the iron phosphate film coating procedures. When micro glass slides are used as the coating substrate, they are dirtier than the silicon wafers, and a two step cleaning process is employed prior to any iron phosphate coating. Water-soluble materials are removed from the glass surface in a water-washstep, followed by an acetone/isopropanol wash step to remove organic contamination from the glass surface.

In determining the need for an undercoating adhesion layer between the substrate and the iron phosphate layer, it is necessary to examine each class of substrates. Silicon wafers can be obtained with or without SiO2 top layers which can be thermally grown. Silicon wafers without SiO2 will require an undercoating adhesion layer. Micro glass slides do not need an undercoating adhesion layer. Plastic strips can also be used as substrates for the optical immunosensor. When we use such plastic strips, we coat the plastic strip surface with a moderately shiny material, e.g., titanium metal. Titanium metal-coated strips require an undercoating adhesion layer.

In our preferred embodiment, we use Ti-isopropoxide solution (0.5 ml in 100ml isopropanol) to obtain an undercoating film of 100 Å Ti(OH). or TiO2 films. A more concentrated solution produces thicker films (2000 Å) of inconsistent quality. When the undercoating is too thin, there is poor adhesion. This poor adhesion occurred when a solution of 0.25 ml Ti-isopropoxide in 100 ml isopropanol was used. It is possible to use silicon dioxide films as the undercoating adhesion films. "Liqui-coat"supplied by Merck is a suitable, commercially available film. Other sol-gelfilms are available, and can be easily identified in the trade journal ThinSolid Films.

When iron phosphate solutions are used to coat the substrate, special safety precautions must be taken in the laboratory. Iron phosphate solution may explode when it is stored in sealed bottles as a result of bubble formation. Loose sealing of vessels containing iron phosphate solutions is recommended, particularly just after the solutions are prepared.

In coating iron phosphate onto a substrate, we use a spin coating technique. Iron phosphate is obtained by mixing FeCl3 (1M) and H3 PO4 (1M) in methanol. Fe(NO3)3 can be dissolved in methanol and combined with or substituted for, the iron chloride. When thenitrate form is used, the resulting film is almost colorless white; films using FeCl3 are yellow. When the subsequent etching step can be performed quickly, we recommend a solution of Fe:PO4 =1:1. When slower etching equipment is used, we recommend 1:1.5 or 1:2. Films made from Fe(NO3)3, 1:1.5 or 1:2, become white after etching. On the contrary, films made from FeCl3, 1:1.5 or 1:2, are very good.

After the iron phosphate layer has been applied, we treat the iron phosphate surface to obtain surface hydroxyl groups which are useful in covalently binding the proteins (mips) to the iron phosphate surface. Ti-isopropoxide solution works well for this "top-coating," even in dilutesolutions (0.25 ml Ti-isopropoxide in 100 ml isopropanol). Once the Ti(OH)4 film is present, we heat the film to -300 C. to convert the Ti(OH)4 to TiO2. At temperatures lower than 300 C. (e.g., 200 C.), water is driven from the Ti(OH)4 film and it becomes tacky which may be adequate for the protein (mip) immobilization. We have not yet undertaken systematic studies to evaluate the performance of detection zones fabricated in each of these two ways. We do understand, however, that lower temperatures are preferable for other reasons because iron phosphate can deteriorate from heating at temperatures in excess of 300 C.

We turn now to the different analyte systems to which this invention can beapplied. The ligand analytes of this invention are characterized by being monoepitopic or polyepitopic. The polyepitopic ligand analytes will normally be poly (amino acids) i.e. polypeptides and proteins, polysaccharides, nucleic acids, and combinations thereof. Such combinations of assemblages include bacteria, viruses, chromosomes, genes,mitochondria, nuclei, cell membranes, and the like.

For the most part, the polyepitopic ligand analytes employed in the subjectinvention will have a molecular weight of at least about 5,000, more usually at least about 10,000. In the poly (amino acid) category, the poly(amino acids) of interest will generally be from about 5,000 to 5,000,000 molecular weight, more usually from about 20,000 to 1,000,000 molecular weight; among the hormones of interest, the molecular weights will usuallyrange from about 5,000 to 60,000 molecular weight.

A wide variety of proteins may be considered: the family of proteins havingsimilar structural features; proteins having particular biological functions, proteins related to specific microorganisms; particularly disease causing microorganisms; etc.

The following are classes of proteins related by structure:

______________________________________protamineshistonesalbuminsglobulinsscleroproteinsphosphoproteinsmucoproteinschromoproteinslipoproteinsnucleoproteinsglycoproteinsproteoglycansunclassified proteins, e.g. somatotropin,prolactin, insulin, pepsinA number of proteins found in the human plasmaare important clinically and include:PrealbuminAlbuminα1 -Lipoproteinα1 -Acid glycoproteinα1 -Antitrypsinα1 -GlycoproteinTranscortin4.6S-PostalbuminTryptophan-poorα1 -Glycoproteinα1 χ-GlycoproteinThyroxin-binding globulinInter-α-trypsin-inhibitorGc-globulin(Gc 1-1)(Gc 2-1)(Gc 2-2)Haptoglobin(Hp 1-1)(Hp 2-1)(Hp 2-2)CeruloplasminCholinesteraseα2 -Lipoprotein(s)MyoglobinC-Reactive Proteinα2 -Macroglobulinα2 -HS-glycoproteinZn-α2 -glycoproteinα2 -Neuramino-glycoproteinErythropoietinβ-lipoproteinTransferrinHemopexinFibrinogenPlasminogenβ2 -glycoprotein Iβ2 -glycoprotein IIImmunoglobulin G(IgG) or γG-globulinMol. formula:γ2 κ2 or γ2 λ2Immunoglobulin A (IgA)or γA-globulinMol. formula:(α2 κ2)n or (α2 λ2).sup.Immunoglobulin M(IgM) or γM-globulinMol. formula:(μ2 κ2)5 or (μ2 λ 2)5(Immunoglobulin D(IgD)or γD-Globulin (γD)Mol. formula:(δ2 κ2) or (δ2 λ2)Immunoglobulin E (IgE)or γE-Globulin (γE)Mol. formula:(ε2 κ2) or (ε2 λ2)Free κ and λ light chainsComplement factors:C'1   C'1q   C'1r   C'1sC'2C'3   β1 A   α2 DC'4C'5C'6C'7C'8C'9Important blood clotting factors include:______________________________________Blood Clotting FactorsInternational designation              Name______________________________________I                  FibrinogenII                 ProthrombinIIa                ThrombinIII                Tissue thromboplastinV and VI           Proaccelerin accelerator              globulinVII                ProconvertinVIII               Antihemophilic globulin              (AHG)IX                 Christmas factor,              plasma thromboplastin              component (PTC)X                  Stuart-Prower factor,              autoprothrombin IIIXI                 Plasma thromboplastin              antecedent (PTA)XII                Hagemann factorXIII               Fibrin-stabilizing              factor______________________________________Important protein hormones include:______________________________________Peptide and Protein HormonesParathyroid hormone(parathromone)ThyrocalcitoninInsulinGlucagonRelaxinErythropoietinMelanotropin(melanocyte-stimulating hormone; intermedin)Somatotropin(growth hormone)Corticotropin(adrenocorticotropic hormone)ThyrotropinFollicle-stimulating hormoneLuteinizing hormone(interstitial cell-stimulating hormone)Luteomammotropic hormone(luteotropin, prolactin)Gonadotropin(chorionic gonadotropin)Tissue HormonesSecretinGastrinAngiotensin I and IIBradykininHuman placental lactogenPeptide Hormones from the NeurohypophysisOxytocinVasopressinReleasing factorsCRF, LRF, TRF, Somatotropin-RF, GRF, FSH-RF,PIF, MIFOther polymeric materials of interest aremucopolysaccharides and polysaccharides.Illustrative antigenic polysaccharides derivedfrom microorganisms are as follows:______________________________________Species of Microorganisms              Hemosensitin Found in______________________________________Streptococcus pyogenes              PolysaccharideDislococcus pneumoniae              PolysaccharideNeisseria meningitidis              PolysaccharideNeisseria gonorrheae              PolysaccharideCorynebacterium diphtheriae              PolysaccharideActinobacillus whitemoriFrancisella tularensis              LipopolysaccharidePasteurella pestis PolysaccharidePasteurella multocida              Capsular antigenBrucella abortus   Crude extractHaemophilus influenzae              PolysaccharideHaemophilus pertussis              CrudeTreponema reiteri  PolysaccharideVeillonella        LipopolysaccharideErysipelothrix     PolysaccharideListeria monocytogenes              PolysaccharideChromobacterium    LipopolysaccharideMycobacterium tuberculosis              Saline extract of 90%              phenol extracted              mycobacteria and              polysaccharide fraction              of cells and tuberculinKlebsiella aerogenes              PolysaccharideKlebsiella cloacae PolysaccharideSalmonella typhosa Lipopolysaccharide              PolysaccharideSalmonella typhi-murium              PolysaccharideSalmonella derbySalmonella pullorumShigella dysenteriae              PolysaccharideShigella sonnei    Crude, PolysaccharideRickettsiae        Crude extractCandida albicans   PolysaccharideEntamoeba histolytica              Crude extract______________________________________

The microorganisms which are assayed may be intact, lysed, ground or otherwise fragmented, and the resulting composition or portion, e.g. by extraction, assayed. Microorganisms of interest include:

______________________________________CorynebacteriaCorynebacterium dipheriaePneumococciDiplococcus pneumoniaeStreptococciStreptococcus pyogenesStreptococcus salivarusStaphylococciStaphylococcus aureusStaphylococcus albusNeisseriaeNeisseria meningitidisNeisseria gonorrheaeEnterobacteriaciaeEscherichia coliAerobacter aerogenes   The coliform bacteriaKlebsiella pneumoniaeSalmonella typhosaSalmonella choleraesuis                  The SalmonellaeSalmonella typhimuriumShigella dysenteriaeShigella schmitziiShigella arabinotardaShigella flexneri      The ShigellaeShigella boydiiShigella sonneiOther enteric bacilliProteus vulgarisProteus mirabilisProteus morgani        Proteus speciesPseudomonas aeruginosaAlcaligenes faecalisVibrio choleraeHemophilus-Pordetella groupHemophilus influenzae,H. ducreyiH. hemophilusH. aegypticusH. parainfluenzaeBordetella pertussisPasteurellaePasteurella pestisPasteurella tulareusisBrucellaeBrucella melitensisBrucella abortusBrucella suisAerobic Spore-forming BacilliBacillus anthracisBacillus subtilisBacillus megateriumBacillus cereusAnaerobic Spore-forming BacilliClostridium botulinumClostridium tetaniClostridium perfringensClostridium novyiClostridium septicumClostridium histolyticumClostridium tertiumClostridium bifermentansClostridium sporogenesMycobacteriaMycobacterium tuberculosis hominisMycobacterium bovisMycobacterium aviumMycobacterium lepraeMycobacterium paratuberculosisActinomycetes (fungus-like bacteria)Actinomyces israeliiActinomyces bovisAntinomyces naeslundiiNocardia asteroidesNocardia brasilienisThe SpirochetesTreponema pallidumTreponema pertenueTreponema carateumBorrelia recurrentisLeptospira icterohemorrhagiaeLeptospira canicolaSpirillum minusStreptobacillus moniliformisMycoplasmasMycoplasma pneumoniaeOther pathogensListeria monocytogenesErysipelothrix rhusiopathiaeStreptobacillus moniliformisDonvania granulomatisBartonella bactillformiRickettsiae (bacteria-like parasites)Rickettsia prowazekiiRickettsia mooseriRickettsia rickettsiiRickettsia conoriRickettsia australisRickettsia sibiricusRickettsia akariRickettsia tsutsugamushiRickettsia burnetiiRickettsia quintanaChlamydia (unclassificable parasites bacteria/viral)Chlamydia agents (naming uncertain)FungiCryptococcus neoformansBlastomyces dermatidisHistoplasma capsulatumCoccidioides immitisParacoccidioides brasiliensisCandida albicansAspergillus fumigatusMucor corymbifer (Absidia corymbifera)Rhizopus oryzaeRhizopus arrhizus    PhycomycetesRhizopus nigricansSporotrichum schenkiiFonsecaea pedrosoiFonsecaea compactaFonsecaea dermatidisCladosporium carrioniiPhialophora verrucosaAspergillus nidulansMadurella mycetomiMadurella griseaAllescheria boydiiPhialosphora jeanselmeiMicrosporum gypseumTrichophyton mentagrophyteskeratinomyces ajelloiMicrosporum canisTrichophyton rubrumMicrosporum andouiniVirusesAdenovirusesHerpes VirusesHerpes simplexVaricella (Chicken pox)Herpes Zoster (Shingles)Virus BCytomegalovirusPox VirusesVariola (smallpox)VacciniaPoxvirus bovisParavacciniaMolluscum contagiosumPicornavirusesPoliovirusCoxsackievirusEchovirusesRhinovirusesMyxovirusesInfluenza (A, B, and C)Parainfluenza (1-4)Mumps VirusNew Castle Disease VirusMeasles VirusRinderpest VirusCanine Distemper VirusRespiratory Syncytial VirusRubella VirusArbovirusesEastern Equine Eucephalitis VirusWestern Equine Eucephalitis VirusSindbis VirusChikugunya VirusSenliki Forest VirusMayora VirusSt. Louis Encephalitis VirusCalifornia Encephalitis VirusColorado Tick Fever VirusYellow Fever VirusDengue VirusReovirusesReovirus Types 1-3HepatitisHepatitis A VirusHepatitis B VirusTumor VirusesRauscher Leukemia VirusGross VirusMaloney Leukemia Virus______________________________________

The monoepitopic ligand analytes will generally be from about 100 to 2,000 molecular weight, more usually from 125 to 1,000 molecular weight. The analytes of interest include drugs, metabolites, pesticides, pollutants, and the like. Included are the alkaloids: morphine alkaloids, which includes morphine, codeine, heroin, dextromethorphan, their derivatives and metabolites; cocaine alkaloids, which includes cocaine and benzoyl ecgonine, their derivatives and metabolites; ergot alkaloids, which includes the diethylamide of lysergic acid; steroid alkaloids; iminazoyl alkaloids; quinazoline alkaloids, isoquinoline alkaloids; quinoline alkaloids; which includes quinine and quinidine; diterpene alkaloids, their derivatives and metabolites.

The next group of drugs includes steroids which includes the estrogens, gestrogens, androgens, adrenocortical steroids, bile acids, cardiotonic glycosides and aglycones, which includes digoxin and digoxigenin, saponinsand sapogenins, their derivatives and metabolites. Also included are the steroid mimetic substances, such as diethylstilbestrol.

The next group of drugs is lactams having from 5 to 6 annular members, which include the barbiturates, e.g. phenobarbital and secobarbital, diphenylhydantoin, primidone, ethosuximide, and their metabolites.

The next group of drugs is aminoalkylbenzenes with alkyl of from 2 to 3 carbon atoms, which includes the amphetamines, catecholamines, which includes ephedrine, L-dopa, epinephrine, narceine, papaverine, and their metabolites.

The next group of drugs is benzheterocyclics which include oxazepam, chlorpromazine, tegretol, imipramine, their derivatives and metabolites, the heterocyclic rings being azepines, diazepines and phenothiazines.

The next group of drugs is purines, which includes theophylline, caffeine, their metabolites and derivatives.

The next group of drugs includes those derived from marijuana, which includes cannabinol and tetrahydrocannabinol.

The next group of drugs includes the vitamins such as A, B, e.g. B12, C, D, E and K, folic acid, thiamine.

The next group of drugs is prostaglandins, which differ by the degree and sites of hydroxylation and unsaturation.

The next group of drugs is antibiotics, which include penicillin, chloromycetin, actinomycetin, tetracycline, terramycin, their metabolites and derivatives.

The next group of drugs is the nucleosides and nucleotides, which include ATP, NAD, FMN, adenosine, guanosine, thymidine, and cytidine with their appropriate sugar and phosphate substituents.

The next group of drugs is miscellaneous individual drugs which include methadone, meprobamate, serotonin, meperidine, amitriptyline, nortriptyline, lidocaine, procaineamide, acetylprocaineamide, propranolol,griseofulvin, valproic acid, butyrophenones, antihistamines, anticholinergic drugs, such as atropine, their metabolites and derivatives.

The next group of compounds is amino acids and small peptides which includepolyiodothyronines e.g. thyroxine, and triiodothyronine, oxytocin, ACTH, angiotensin, met-and lu-enkephalin their metabolites and derivatives.

Metabolites related to diseased states include spermine, galactose, phenylpyruvic acid, and porphyrin Type 1.

The next group of drugs is aminoglycosides, such as gentamicin, kanamycin, tobramycin, and amikacin.

Among pesticides of interest are polyhalogenated biphenyls, phosphate esters, thiophosphates, carbamates, polyhalogenated sulfenamides, their metabolites and derivatives.

For receptor analytes, the molecular weights will generally range from 10,000 to 2106, more usually from 10,000 to 106. For immunoglobulins, IgA, IgG, IgE and IgM, the molecular weights will generally vary from about 160,000 to about 106. Enzymes will normallyrange from about 10,000 to 6,000,000 in molecular weight. Natural receptorsvary widely, generally being at least about 25,000 molecular weight and maybe 106 or higher molecular weight, including such materials as avidin,thyroxine binding globulin, thyroxine binding prealbumin, transcortin, etc.

The optical immunosensor of the present invention can be used qualitatively, semi-quantitatively or quantitatively. When the device is used semi-quantitatively, the user can be directed that certain color changes correspond to particular concentration levels of the target analyte. When the device is utilized for quantitative measurement, a reference device is employed with the sensor device under the same liquid sample conditions. For example, a single wafer can be marked with two channels, one the testing/sensor channel, and the other the reference channel. If the concentration of protein on the reference channel is known(i.e., concentration of protein is proportional to thickness is related to color) then the sensor channel can be quantified by reference to the colorchanges as compared to the reference channel, which will not undergo any color change upon exposure to the liquid sample.

WORKING EXAMPLES Example 1

Using a silicon wafer as a substrate, steps of FePO4 were made according to the following procedure:

An iron phosphate solution was obtained by mixing FeCl3 (1M) and H3 PO4 (1M) in methanol. This solution was then spin coated ontoa silicon wafer at 5000 RPM and ambient temperatures. The resulting iron phosphate layer was then etched with H3 PO4. Steps of varying iron phosphate thickness were obtained by dipping the coated wafer into the acid at different lengths and for different times. Interference colorswith sharp contrast were obtained between steps.

Example 2

A silicon substrate with iron phosphate steps was left in contact with a 10% solution of albumin overnight. When the steps were removed from the albumin solution and the solution was allowed to evaporate from the surface, essentially albumin dried on the steps resulting in a thickness change. This thickness change was manifested by a shift in colors of several steps, indicating that thickness changes can be monitored by this procedure. However, when the albumin was washed with a jet of water, most of the albumin was washed away as seen by only a faint change in color. This was interpreted to mean that the albumin was probably not adsorbed onthe FePO4 surface.

An iron phosphate solution was obtained by mixing FeCl3 (1M) and H3 PO4 (1M) in methanol. This solution was then spin coated ontoa silicon wafer at 5000 RPM and ambient temperatures. The resulting iron phosphate layer was then etched with H3 PO4. Steps of varying iron phosphate thickness were obtained by dipping the coated wafer into the acid at different lengths and for different times. Interference colorswith sharp contrast were obtained between steps.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2351644 *Aug 22, 1942Jun 20, 1944Shell DevCorrosion testing element
US3853467 *Aug 15, 1973Dec 10, 1974Gen ElectricMethod and apparatus for immunological detection of biological particles
US4810470 *Jun 19, 1987Mar 7, 1989Miles Inc.Volume independent diagnostic device
US4820649 *Sep 22, 1987Apr 11, 1989Teijin LimitedMethod and kit having layered device for detecting biological component by interference color
US5063081 *Aug 15, 1990Nov 5, 1991I-Stat CorporationMultilayer; permselective layer, photoformable proteinaceous photoresist amd overcoating of immobilized ligand receptor
Non-Patent Citations
Reference
1Biostar promotional materials, J. Hanlin, "Thin Films," Photonics Spectra (Feb. 1988) pp. 113-118.
2 *Biostar promotional materials, J. Hanlin, Thin Films, Photonics Spectra (Feb. 1988) pp. 113 118.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5484745 *Oct 26, 1993Jan 16, 1996Yazaki Meter Co., Ltd.Method for forming a semiconductor sensor
US5528070 *Oct 6, 1994Jun 18, 1996Yazaki Meter Co., Ltd.Semiconductor sensor manufactured through anodic-bonding process
US5545594 *Oct 26, 1993Aug 13, 1996Yazaki Meter Co., Ltd.Semiconductor sensor anodic-bonding process, wherein bonding of corrugation is prevented
US5550063 *Jun 10, 1993Aug 27, 1996Biostar, Inc.Methods for production of an optical assay device
US5750357 *Jan 30, 1995May 12, 1998Microquest Diagnostics, Inc.Synthetic copolymer containing monomer units that are binding sites and labels
US5958704 *Mar 12, 1997Sep 28, 1999Ddx, Inc.Sensing system for specific substance and molecule detection
US6274384Jul 6, 1999Aug 14, 2001Accelr8 Technology CorporationMethod for specific substance and molecule detection
Classifications
U.S. Classification422/424, 436/525, 436/810, 436/808
International ClassificationG01N33/543, G01N33/553
Cooperative ClassificationY10S436/81, Y10S436/808, G01N33/553, G01N33/54373, G01N33/54393
European ClassificationG01N33/543M, G01N33/543K2, G01N33/553
Legal Events
DateCodeEventDescription
Feb 13, 2001FPExpired due to failure to pay maintenance fee
Effective date: 20001208
Dec 10, 2000LAPSLapse for failure to pay maintenance fees
Jul 4, 2000REMIMaintenance fee reminder mailed
Jan 2, 1996FPAYFee payment
Year of fee payment: 4
May 16, 1994ASAssignment
Owner name: TEKNEKRON CORPORATION, NEVADA
Free format text: CONVEYANCE AGREEMENT;ASSIGNOR:TEKNEKRON SENSOR DEVELOPMENT CORPORATION;REEL/FRAME:006987/0902
Effective date: 19940427
Aug 30, 1990ASAssignment
Owner name: TEKNEKRON SENSOR DEVELOPMENT CORPORATION, CALIFORN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:JOSEPH, JOSE P.;ITOH, KIMINORI;REEL/FRAME:005444/0405
Effective date: 19900814